Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Pancreatic Cancer
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
https://ascopubs.org/doi/10.1200/JCO-25-00746
Related Questions
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?
When treating pancreatic body/tail lesions that result in significant dose spread to the spleen, what is your threshold to offer pneumococcal, hemophilus influenza, and meningococcal vaccines?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
What are your top takeaways from ASCO GI 2025?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
Which GI cancer patients do you use oral contrast in staging CT scans?
When would you opt to manage anal squamous cell carcinoma, HPV+ with surveillance vs adjuvant treatment following a trans-anal excision?
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
When treating primary liver disease with radiation, how do you contour and constrain the central bile ducts?
